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Abstract
Metabotropic glutamate 2 receptors (mGlu2) are involved in the pathogenesis of several CNS 
disorders and neurodegenerative diseases. Pharmacological modulation of this target represents a 
potential disease-modifying approach for the treatment of substance abuse, depression, 
schizophrenia and dementias. While quantification of mGlu2 receptors in the living brain by 
positron emission tomography (PET) would help us better understand signaling pathways relevant 
to these conditions, few successful examples have been demonstrated to image mGlu2 in vivo and 
a suitable PET tracer is yet to be identified. Herein we report the design and synthesis of a 
radiolabeled negative allosteric modulator (NAM) for mGlu2 PET tracer development based on a 
quinoline 2-carboxamide scaffold. The most promising candidate, 7-((2,5-dioxopyrrolidin-1-
yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide ([11C]QCA) was 
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prepared in 13% radiochemical yield (non-decay corrected at the end of synthesis) with >99% 
radiochemical purity and >74 GBq/µmol (2 Ci/µmol) specific activity. While the tracer showed 
limited brain uptake (0.3 SUV), probably attributable to effects on PgP/Bcrp efflux pump, in vitro 
autoradiography studies demonstrated heterogeneous brain distribution and specific binding. Thus, 




positron emission tomography; metabotropic glutamate receptor 2; mGlu2; 11C; negative allosteric 
modulator
INTRODUCTION
Glutamate is the most abundant endogenous excitatory neurotransmitter and glutamate 
receptors (Glus) play a pivotal role in modulating a wide scope of neurological functions in 
the central nervous system (CNS).1–6 Glutamatergic signaling is primarily mediated via two 
distinct groups, namely ionotropic receptors (iGlus) and the G protein-coupled metabotropic 
receptors (mGlus). Based on different sequence homology, anatomical distribution and 
pharmacology, the mGlus are typically divided into three subcategories. Group I mGlus 
(mGlu1 and mGlu5), coupled to Gq/G11 proteins, mobilize calcium from intracellular stores 
upon activation and increase protein kinase C activity. Group II (mGlu2 and mGlu3) and 
Group III (mGlu4, mGlu6, mGlu7 and mGlu8) mGlus, coupled to Gi/o proteins, downregulate 
cAMP formation through inhibition of adenylyl cyclase.7 In particular, mGlu2 receptors 
negatively regulate endogenous glutamate release and consequently may be involved in the 
protection of neurons against excitotoxicity. The receptors are predominantly localized on 
presynaptic membranes although they are also found in peripheral regions of the synapse.8,9 
Moderate-to-high expression of mGlu2 can be found in many brain regions, including the 
cerebral cortex, cerebellum, amygdala and hippocampus.10–14 It has been reported that 
mGlu2 is involved in the pathogenesis of numerous brain dysfunctions, including psychiatric 
disorders and neurodegenerative diseases.7,15–19 Therefore pharmacological modulation of 
mGlu2 represents a promising therapeutic approach for the treatment of several CNS 
diseases,20 including drug dependence,21–23 chronic pain,24 anxiety,17 depression,25,26 
schizophrenia,27 Parkinson’s disease28,29 and Alzheimer’s disease.30 Initial drug discovery 
efforts focused on non-selective mGlu2/3 agonists and antagonists that bind to the mGlu 
orthosteric binding site (evolutionarily conserved glutamate binding site);31 however, in 
recent years there has been a shift towards allosteric modulation strategies (consisting of 
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positive and negative allosteric modulators; abbreviated as PAM and NAM, respectively) 
that offer the potential for improved selectivity for mGlu2 or mGlu3.32,33 While a wide range 
of highly selective mGlu2 PAMs have been discovered and recently reviewed,33,34 the 
development of selective mGlu2 NAMs has remained in its nascent stage with only one 
report based on a dihydroquinoline 2-carboxamide scaffold in the primary literature.35
Positron emission tomography (PET) is a non-invasive imaging technology that is capable of 
quantifying biochemical processes in vivo,36–39 which would enable investigations of mGlu2 
based glutamatergic signaling under normal and disease conditions, and assessment of 
distribution and testing target engagement and dose occupancy of mGlu2 drug candidates for 
clinical trials. Unlike several mGlu1 or mGlu5-targeting PET radiotracers in human use,40–45 
there is an unmet need for probing mGlu2 in clinical research and drug development towards 
this important receptor subtype in the glutamatergic pathway. As shown in Figure 1, there 
are continuous research efforts in the development of mGlu2 PET tracers,40–43 including 
[11C]CMGDE (1),46,47 [11C]JNJ-42491293 (2),48,49 [18F]FE-JNJ42491293 (3),50 
[11C]CMDC (4)51 and two tracers (18F-compound 5 and 11C-compound 6) in the patent 
literature.52,53 Among these studies [11C]CMGDE (1), the first mGlu2 radiotracer based on a 
prodrug of an antagonist LY341495, provided a foundation for the further development of a 
specific mGlu2 tracer.47 On the other hand [11C]CMDC (4), a derivative of JNJ-40068782,54 
was not further pursued due to limited brain penetration (peak brain uptake ca. 0.6 SUV).51 
Preliminary evaluation in PET imaging studies for compounds 3, 5, 6 are not yet disclosed 
for the development of mGlu2 tracers.52,53 Only two PET tracers, namely 
[11C]JNJ-42491293 (2) and a 11C-compound from Merck, have been advanced to first-in-
human studies. [11C]JNJ-42491293 (2) was discontinued for mGlu2 imaging due to 
unexpected off-target binding in vivo during clinical trials55,56 and only limited preliminary 
data on the Merck compound (no structural information) were reported in abstracts.57,58 
These mGlu2 imaging efforts combined with pharmaceutical development and the potential 
of mGlu2-modulating pharmacotherapy provide a strong impetus to advance PET tracer 
development for this target.
Herein we describe the synthesis of a small array of potent and selective mGlu2 NAMs that 
are amenable for radiolabeling and their preliminary evaluation in rodents by PET. In vitro 
autoradiography studies confirm the specific binding of these new NAMs bearing a 




We designed a focused library of small molecule based on a series of NAMs disclosed in the 
patent literature,59 with the goal to develop a selective mGlu2 PET tracer amenable to 
radiolabeling with either 11C or 18F. In particular, the succinimidyl compound 16 was 
selected in our proof-of-concept studies because of reported low EC50 value (8 nM), 
reasonable cLogP value (2.95) and amenability for 11C-labeling from its corresponding 
phenolic precursor. Thus a set of quinolone 2-carboxamides and their labeling precursors 
were synthesized according to our synthetic strategy (see detailed retrosynthetic analysis in 
Zhang et al. Page 3













Scheme S1 of Supporting Information, SI). As summarized in Scheme 1, oxidation of 7-
methylquinoline (7) with mCPBA followed by cyanide addition provided quinoline-2-
carbonitrile 8 in 74% yield over two steps, which was converted to chloroquinoline 9 after 
mCPBA oxidation and POCl3 chlorination (60% yield). Site-specific bromination at the 
benzyl position of chloroquinoline 9 followed by succinimide substitution gave key 
intermediate 11 in 80% yield. Several parallel syntheses were carried out to introduce aryl 
groups at the ipso position of the chloride via palladium catalyzed Suzuki cross-coupling 
reactions. The coupling reaction with (2-fluoro-4-methoxyphenyl)boronic acid gave 
quinoline nitrile 12, which was hydrolyzed in basic H2O2 solution to afford the final 
standard 7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-methoxyphenyl)quinoline-2-
carboxamide (QCA; 16) in 55% yield over 2 steps. The cross coupling procedure was also 
applied to obtain phenol 17 (51% yield), fluoroethyl (FEPAD (18), 60% yield) and 
fluoropropyl derivatives (FPPAD (19), 53% yield). In brief, the synthesis of QCA (16), its 
precursor 17 and fluorinated derivatives (18–19) were achieved in eight to nine steps with 
overall yields of 6% - 10%.
Pharmacology and physicochemical properties
QCA and its two fluorinated derivatives (FEQCA and FPQCA) were subsequently screened 
for their in vitro activity towards mGlu2 and mGlu3, and the results are shown in Figure 2. A 
thallium flux assay in human embryonic kidney 293 (HEK) cells expressing heteromeric G-
protein coupled inwardly rectifying potassium (GIRK) channels60 and human mGlu2 or 
mGlu3, was utilized to determine potency, efficacy and selectivity. The concentration-
response relationship that antagonizes the effect of an EC80 concentration of glutamate was 
determined for each candidate. Potency is expressed as the IC50 for inhibition of the 
glutamate EC80 response. All three candidates showed NAM activity (IC50 values 45 ± 5 nM 
for QCA, 130 ± 10 nM for FEQCA, and 1080 ± 1300 nM for FPQCA) at human mGlu2 and 
excellent selectivity for mGlu2 over mGlu3. We utilized MNI-137, a mGlu2/3 NAM, as a 
positive control in our GIRK assay,61 and found no evidence of mGlu3 potencies up to the 
highest concentration of 30 µM. In addition, QCA was inactive towards other mGlu 
receptors at the test concentration of 30 µM, and showed no significant interaction with 
major CNS targets, which was conducted via GPCRome assays62 developed by the NIH 
PDSP program. (see excel data sheet in the associate content).
We next evaluated whether QCA inhibits mGlu2 by a competitive or noncompetitive 
mechanism of action in functional studies by performing a Schild analysis.63 For these 
studies, the concentration-response relationships of glutamate-induced increases in thallium 
flux were evaluated for both mGlu2 and mGlu3 in the absence or presence (30 µM, 10 µM, 
3333 nM, 1111 nM, 370 nM, 123 nM, or 41 nM) of QCA (Figure 3). QCA dose-
dependently right-shifted the concentration-response of glutamate toward mGlu2 (Figure 
3A) and decreased the maximal glutamate response, consistent with a noncompetitive mode 
of action. Alternatively, consistent with the previous in vitro studies (Figure 2B), QCA had 
no effect on either the glutamate potency or glutamate maximal response toward mGlu3 
(Figure 3B), which also serves as an additional control demonstrating the mGlu2 selectivity 
of QCA.
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Lipophilicity of candidate compounds can be used as a predictive parameter for assessing 
blood-brain barrier permeability, with preferred range of 1.0–3.5.64–66 The cLogP values of 
compounds QCA (16), FEQCA (18) and FPQCA (19) were predicted to be 2.95, 3.44 and 
3.69, respectively, using Pallas 3.0 prediction software (Table 1). Using liquid-liquid 
partition between n-octanol and water (“shake flask method”),67 the LogP values for QCA, 
FEQCA, and FPQCA were 1.27 ± 0.29, 1.75 ± 0.14 and 1.99 ± 0.12, respectively. Since in 
vitro assessments of pH stability, plasma and microsomal stability are important to the initial 
selection of candidate compounds,68 we carried out preliminary experiments to determine 
these parameters. We first evaluated the stability of the compounds under physiological 
conditions (pH = 5.0–9.4). All three compounds showed excellent stability at pH 5 and 
diminished stability at pH 7.4 and 9.4 at 37°C, which may be attributed to hydrolysis of 
succinimidyl group at higher pH. In addition, QCA and its fluorinated derivatives showed 
reasonable plasma and microsomal stability. Based on the functional assay results (cf. Figs. 
2 & 3) and physicochemical properties (cf. Table 1), QCA (16) exhibited the lowest EC50 
value among all derivatives and reasonable lipophilicity and plasma/microsomal stability, 
which warrants further radiolabeling and subsequent evaluation by in vivo PET imaging and 
ex vivo biodistribution studies.
Radiochemistry
As shown in Scheme 2, there are three possible labeling strategies for QCA (16), namely 
(1) 11C-cyanation followed by H2O2 hydrolysis from 2-chloroquinoline precursor; (2) 11C-
carbonylation via [11C]CO followed by aminolysis from 2-chloroquinoline precursor and 
(3) 11C-methylation from the the phenolic precursor 17. Although the first two approaches 
may entail a general and unified strategy for the formation of 11C-carbonyl labeled quinoline 
carboxamides, as proof of concept, we chose the most convenient phenolic site for QCA 
labeling. The radiosynthesis of [11C]QCA was performed by the reaction of the phenolic 
precursor 17 (0.5 mg) with [11C]CH3I in the presence of NaOH (1.25 µmol) in DMF (300 
µL). The reaction was carried out at 80 °C for 5 min, followed by purification using semi-
preparative HPLC. Specifically, [11C]QCA was obtained from the reaction between its 
phenolic precursor and [11C]CH3I. The radiochemical yield was 13 ± 4% non-decay 
corrected (n = 3), calculated from starting [11C]CO2. The [11C]QCA was then reformulated 
in a saline solution containing 100 µL of 25% ascorbic acid in sterile water and 100 µL of 
20% Tween® 80 in ethanol at the end of synthesis (see details in Methods). The 
radiochemical and chemical purity were greater than 99% and specific activity was greater 
than 74 GBq/µmol (2 Ci/µmol). The overall synthesis time was ca. 30 min and no radiolysis 
was observed up to 90 min.
Whole body biodistribution studies in mice
The uptake, distribution and clearance of [11C]QCA ([11C]16) were studied in mice at five 
time points (1, 5, 15, 30 and 60 min) post tracer injection. The results are expressed as the 
percentage of the injected dose per gram of wet tissue (%ID/g) in Figure 4 and Table S1 (SI) 
and standardized uptake value (SUV) in Figure S1 and Table S2 (SI). High uptake (>3% 
ID/g) was observed in the heart, lungs, liver, pancreas, kidneys and small intestine at 1 min 
post injection of [11C]QCA. After the initial phase the radioactivity levels in most tissues 
decreased rapidly, while the signals in the liver and small intestine continually increased 
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until 30 min and then decreased slowly. The radioactivity was efficiently cleared from blood 
(1 min/60 min ratio of 2.4) and high radioactivity in the liver, kidneys and small intestine 
indicated urinary and hepatobiliary excretion, as well as a possible intestinal reuptake 
pathway. The distribution of [11C]QCA in the peripheral organs was similar to prior reports 
with other compounds,51,56,69,70 in which rapid clearance of radioactivity from heart, lungs, 
spleen and muscle was observed. Limited brain uptake (peak value 0.42% ID/g at 1 min post 
injection) was observed, and thus the regional brain distribution was further studied by in 
vitro autoradiography.
In vitro Autoradiography
The binding specificity of [11C]QCA to mGlu2 was confirmed by in vitro autoradiography. 
Representative in vitro autograms of [11C]QCA on sagittal sections of rat brains are shown 
in Figure 5A. In the baseline study, the distribution of bound radioactivity was 
heterogeneous with signal levels from high to low in the order of cerebral cortex, striatum, 
hippocampus, cerebellum and pons/medulla (Figure 5B). These autographic results are in 
agreement with both the previously published distribution of mGlu2 in rat brain,10,12 and 
with other autoradiography studies with the mGlu2 radioligands [11C]CMDC,51 
[3H]JNJ-40068782,54 [3H]LY34149571 and [3H]LY459477.14 As shown in Figure 5C, 
quantitative analysis of radioactivity binding in the mGlu2-rich regions (cerebral cortex, 
striatum, hippocampus and cerebellum) with unlabeled QCA (1 µM) and a NAM MNI-13761 
(1 µM) showed ca. 50–60% reduced binding compared with that of baseline. We also 
observed marginal reductions (ca. 10–20%) of radioactivity binding when a mGlu2 PAM 
LY48737972 was used for blocking study, which may indicate a possible shared, yet at a low 
level, binding site between positive and negative allosteric modulators.73,74 These results 
indicate that [11C]QCA has a moderate-to-high level of in vitro specific binding to mGlu2 
and the binding mechanism is consistent with that of a negative allosteric modulator.
PET imaging studies in normal rat brain
Dynamic PET acquisitions were carried out with [11C]QCA in Sprague-Dawley rats for 60 
min. Representative PET images (summed 0–60 min) in whole brain and time-activity 
curves are shown in Figure 6. The tracer [11C]QCA showed limited brain uptake (ca. 0.3 
SUV whole brain) in rat and no obvious washout (ratio of SUV5 min/SUV90 min = 1.1). 
Pretreatment with unlabeled QCA (1 mg/kg) failed to show significant reduction of brain 
uptake, likely attributed to low brain permeability and possible in vivo non-specific binding 
(Figure 6C). We next carried out radiometabolite analysis and PET imaging in PgP/Bcrp 
knockout mice to investigate possible reasons of limited CNS penetration.
Radiometabolite analysis
To evaluate the in vivo stability of [11C]QCA, radiometabolites in the plasma and brain 
homogenate of Sprague-Dawley rats were evaluated post-tracer injection. The percentages 
of unchanged [11C]QCA and the corresponding radiometabolites, as determined by radio-
HPLC, are shown in Figure 7. The fraction corresponding to unchanged [11C]QCA in 
plasma was 93% at 5 min, 88% at 20 min and 79% at 60 min, respectively, with only one 
other more polar metabolite observed (Top three possible sites for the metabolism are 
predicted by SMARTCyp75 and the results are listed as Table S3 in the supporting 
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information). Analysis of rat brain homogenates in the same time interval showed 
unchanged [11C]QCA was 78%, 41% and 34%, respectively, with the same radiometabolite 
as found in plasma. These results indicate that the resulting polar radiometabolite may be 
brain penetrant.
PET imaging studies in PgP/Bcrp knockout mice
Based on the results of in vitro autoradiography and in vivo PET studies on rat brain, we 
speculated that insufficient brain permeability of [11C]QCA might be induced by ATP-
binding cassette efflux transporters located at the blood-brain barrier,66,76–79 particularly, P-
glycoprotein (PgP, ABCB1) and breast cancer resistance protein (Bcrp, ABCG2). To test this 
hypothesis, we carried out PET imaging studies of [11C]QCA on wild-type and PgP/Bcrp 
knockout (ABCB1a/1b−/−ABCG2−/−) mice, and compared pharmacokinetic profiles, 
particularly brain uptake and clearance.
As shown in Figure 8, peak brain uptake in whole brain was ca. 0.8 SUV in PgP/Bcrp 
knockout mice, indicating a significant difference compared with that (ca. 0.3 SUV) of the 
wild-type mice. Whole brain uptake increased 130% in PgP/Bcrp knockout mice compared 
with that of wild-type mice (calculated based on area under curve). Therefore these results 
indicated that [11C]QCA had intensive interactions with brain efflux pumps on the murine 
blood-brain barrier and is likely a PgP/Bcrp substrate in rodents.
CONCLUSION
We have efficiently synthesized a focused library of NAMs targeting mGlu2, and 
radiolabeled the most promising ligand, namely [11C]QCA in good radiochemical yield, 
high radiochemical purity and high specific activity. The pharmacokinetic profile (ex vivo 
distribution, uptake and clearance), in vitro autoradiography, brain penetration, efflux pump 
and metabolism studies were evaluated to determine the suitability of [11C]QCA as a mGlu2 
tracer. While [11C]QCA is not likely pursued for in vivo mapping of mGlu2 due to limited 
brain permeability, in vitro specific binding studies by autoradiography showed promise as a 
new chemotype for mGlu2 tracer development. Further SAR studies of succinimidyl and/or 
quinoline carboxamide functionality are necessary to test PgP/Bcrp efflux liability and to 
facilitate next generation tracer design with improved brain permeability. In-depth 
pharmacology evaluation is equally important to validate in vivo specificity using mGlu2 
knockout mice and/or mGlu2-specific NAMs. Radiotracer’s binding will also be evaluated 
under different agonist concentrations to characterize and select NAM- or PAM-based tracer 
for future clinical translation.”
METHODS
Materials and Methods
General Consideration—All the chemicals employed in the syntheses were purchased 
from commercial vendors and used without further purification. Thin-layer chromatography 
(TLC) was conducted with 0.25 mm silica gel plates (60F254) and visualized by exposure to 
UV light (254 nm) or stained with potassium permanganate. Flash column chromatography 
was performed using silica gel (particle size 0.040–0.063 mm). H-Nuclear magnetic 
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resonance (NMR) spectra were obtained on a 300 MHz on Bruker spectrometers and 13C 
NMR spectra were obtained at 75 MHz. Chemical shifts (δ) are reported in ppm and 
coupling constants are reported in Hertz. The multiplicities are abbreviated as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, sept = setpet, m = 
multiplet, br = broad signal, dd = doublet of doublets. For LC-MS/MS measurements, the 
ionization method is ESI using Agilent 6430 Triple Quad LC/MS. Lipophilicity was 
calculated by Pallas 3.4 ADME prediction software (CompDrug International, Inc., USA). 
The animal experiments were approved by the Institutional Animal Care and Use Committee 
of Massachusetts General Hospital or the Animal Ethics Committee at the National Institute 
of Radiological Sciences. DdY mice (male; 7 weeks, 34–36 g), Pgp/Bcrp knockout 
(Abcb1a/1b−/−Abcg2−/−; male; 17–18 weeks old; 31–33 g), wild-type (male; 17–18 weeks 
old; 30–32 g) FAB mice and Sprague-Dawley rats (male; 7 weeks; 210–230 g) were kept on 
a 12 h light/12 h dark cycle and were allowed food and water ad libitum.
Chemistry
7-methylquinoline-2-carbonitrile (8)—7-methylquinoline (10 g, 57.9 mmol) was 
dissolved in dichloromethane (200 mL) in a round bottom flask with a stir bar. 3-
Chloroperoxybenzoic acid (14.4 g, 75%, 75.33 mmol) was added in portions with ice bath. 
The mixture was stirred at room temperature overnight, then quenched with 400 mL 1N 
NaOH(aq.) and extracted with dichloromethane (200 mL × 3). The combined organic layers 
were washed with saturated aqueous sodium bicarbonate, dried over MgSO4 and 
concentrated to give 7-methylquineline N-oxide. The crude product was used without further 
purification. To a solution of 7-methylquinoline N-oxide in dichloromethane (200 mL) was 
added trimethylsilyl cyanide (11.9g, 120.6 mmol) and dimethylcarbamoyl chloride (13.0 g 
120.6 mmol). The mixture was stirred at room temperature overnight, then quenched with 
saturated sodium bicarbonate and extracted with dichloromethane (200 mL × 3). The 
combined organic layers were washed with saturated aqueous sodium chloride, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography on 
silica gel (hexanes to ethyl acetate gradient column) to yield the compound 8 as white solid 
(7.3 g, 74% over two steps). Rf = 0.3 (Hexanes/EtOAc = 20:1). 1H NMR (400 MHz, CDCl3) 
δ 8.27 (d, J = 8.3 Hz, 1H), 7.95 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 
7.58 – 7.52 (m, 1H), 2.62 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 148.3, 142.1, 137.1, 
133.3, 131.8, 128.6, 127.3, 126.8, 122.6, 117.5, 21.9.
4-chloro-7-methylquinoline-2-carbonitrile (9)—Compound 8 (7.0 g, 41.6 mmol) was 
dissolved in dichloromethane (300 mL) in a round bottom flask with a stir bar. 3-
Chloroperoxybenzoic acid (28.7 g, 75%, 124.8 mmol) was added in portions with ice bath. 
The mixture was stirred at 40°C for 3 h, then additional 3-chloroperoxybenzoic acid (28.7 g, 
75%, 124.8 mmol) was added. The mixture was stirred at room temperature overnight, then 
quenched with 400 mL 1N NaOH(aq.) and extracted with dichloromethane (200 mL × 3). 
The combined organic layers were washed with saturated aqueous sodium bicarbonate, dried 
over MgSO4 and concentrated to give 4-chloro-7-methylquinoline-2-carbonitrile N-oxide. 
The crude product was used without further purification. To a solution of 4-chloro-7-
methylquinoline-2-carbonitrile N-oxide in chloroform (200 mL) was added DMF (3.0 g, 
41.3 mmol). Then POCl3 (38.0 g, 247.6 mmol) was added in three portions at 70°C in 4 h. 
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The mixture was stirred at 70 °C for 2 h before pour into iced water and extracted with 
dichloromethane (200 mL × 3). The combined organic layers were washed with saturated 
aqueous sodium chloride, dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (hexanes to ethyl acetate gradient column) to 
yield the compound 9 as white solid (5.4 g, 64% over two steps). Rf = 0.3 (Hexanes/EtOAc 
= 20:1). 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 8.6 Hz, 1H), 8.00 – 7.91 (m, 1H), 7.72 
(s, 1H), 7.64 (dd, J = 8.7, 1.7 Hz, 1H), 2.62 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 149.0, 
143.7, 143.0, 133.1, 132.8, 129.2, 125.3, 123.8, 122.5, 116.7, 21.8.
7-(bromomethyl)-4-chloroquinoline-2-carbonitrile (10)—To a solution of the 
compound 9 (1.17 g, 5.76 mmol) in CCl4 (110 mL) under Ar was added N-
bromosuccinimide (1.13 g, 6.33 mmol) and benzoyl peroxide (139.50 mg, 0.579 mmol). The 
mixture was stirred at 85°C for 4 h, then quenched with water (50 mL) and extracted with 
dichloromethane (100 mL × 3). The combined organic layers were washed with saturated 
aqueous sodium chloride, dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (hexanes to ethyl acetate gradient column) to 
yield the compound 10 as white solid (60%, 967 mg). Rf = 0.2 (Hexanes/EtOAc = 20:1). 1H 
NMR (400 MHz, CDCl3) δ 8.29 (d, J = 8.6 Hz, 1H), 8.17 (s, 1H), 7.84 (d, J = 8.6 Hz, 1H), 
7.80 (s, 1H), 4.68 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 148.7, 144.0, 142.1, 133.8, 131.4, 
129.8, 126.8, 125.1, 123.7, 116.4, 31.5.
4-chloro-7-((2,5-dioxopyrrolidin-1-yl)methyl)quinoline-2-carbonitrile (11)—To a 
solution of the compound 10 (719 mg, 2.55 mmol) and succinimide (303 mg, 3.06 mmol) in 
DMF (15 mL) was added Cs2CO3 (1.66 g, 5.11 mmol). The mixture was stirred at room 
temperature for 0.5 h, then quenched with saturated aqueous KH2PO4 (40 mL) and extracted 
with ethyl acetate (40 mL × 3). The combined organic layers were washed with saturated 
aqueous sodium chloride, dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (hexanes to ethyl acetate gradient column) to 
yield the compound 11 as white solid (80%, 612 mg). Rf = 0.2 (Hexanes/EtOAc = 1:1). 1H 
NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.7 Hz, 1H), 8.09 (s, 1H), 7.80 (d, J = 8.8 Hz, 1H), 
7.77 (s, 1H), 4.92 (s, 2H), 2.81 (s, 4H). 13C NMR (100 MHz, CDCl3) δ 176.5, 148.7, 144.0, 
140.0, 133.6, 130.9, 129.3, 126.6, 124.8, 123.4, 116.4, 41.8, 28.2.
7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-methoxyphenyl)quinoline-2-
carboxamide (QCA; 16)—To a solution of the 2-fluoro-4-methoxyphenylboronic acid 
(54.4 mg, 0.320 mmol) and Na2CO3 (56.6 mg, 0.534 mmol) in 1,4-dioxane : water (v/v, 
10/1, 1.8 mL) was added compound 11 (80.0 mg, 0.267 mmol) and Pd(PPh3)4 (30.9 mg, 
0.0267 mmol) under Ar. The mixture was stirred at 100°C for 4 h, then quenched with water 
(3 mL) and extracted with ethyl acetate (5 mL × 3). The combined organic layers were 
washed with saturated aqueous sodium chloride, dried over MgSO4 and concentrated in 
vacuo. The residue was used without further purification. To the residue solution in acetone : 
water (v/v, 2/1, 15 mL) was added sodium percarbonate (0.251 g, 1.60 mmol). The mixture 
was stirred at room temperature for 4h, then added ethyl acetate (5 mL) and extracted with 
ethyl acetate (5 mL × 3). The residue was purified by flash chromatography on silica gel 
(hexanes to ethyl acetate gradient column) to yield QCA (16) as white solid (42% for two 
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steps, 55 mg). Rf = 0.2 (Hexanes/EtOAc = 1:3). 1H NMR (300 MHz, DMSO-d6) δ 8.02 (s, 
1H), 8.01 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.69 – 7.56 (m, 2H), 7.46 (t, J = 8.6 Hz, 1H), 
6.86 – 6.72 (m, 2H), 4.78 (s, 2H), 3.87 (s, 3H), 2.73 (s, 4H). 13C NMR (75 MHz, DMSO-d6) 
δ 178.1, 166.4, 161.9 (d, J = 11.0 Hz), 160.0 (d, J = 244.1 Hz), 150.8, 146.8, 143.7, 139.2, 
132.6 (d, J = 4.9 Hz), 128.9, 128.3, 126.8, 126.3, 120.0, 116.7 (d, J = 15.9 Hz), 111.6, 102.4 
(d, J = 25.4 Hz), 56.3, 41.6, 28.7.
7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-hydroxyphenyl)quinoline-2-
carboxamide (17)—To a solution of the 2-fluoro-4-hydroxyphenylboronic acid (50 mg, 
0.320 mmol) and Na2CO3 (56.6 mg, 0.534 mmol) in 1,4-dioxane : water (v/v, 10/1, 1.8 mL) 
was added compound 11 (80.0 mg, 0.267 mmol) and Pd(PPh3)4 (30.9 mg, 0.0267 mmol) 
under Ar. The mixture was stirred at 100°C for 4 h, then quenched with water (3 mL) and 
extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with 
saturated aqueous sodium chloride, dried over MgSO4 and concentrated in vacuo. The 
residue was used without further purification. To the residue solution in acetone : water (v/v, 
2/1, 1.5 mL) was added sodium percarbonate (0.251 g, 1.60 mmol). The mixture was stirred 
at room temperature for 4 h, then added ethyl acetate (5mL) and extracted with ethyl acetate 
(5 mL × 3). The residue was purified by flash chromatography on silica gel (hexanes to ethyl 
acetate gradient column) to yield the compound 13 as white solid (39% for two steps, 49 
mg). Rf = 0.2 (Hexanes/EtOAc = 1:3). 1H NMR (300 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.31 
(s, 1H), 8.01 (s, 1H), 7.96 (s, 1H), 7.81 (s, 1H), 7.71 – 7.66 (m, 2H), 7.34 (t, J = 8.6 Hz, 1H), 
6.86 – 6.72 (m, 2H), 4.78 (s, 2H), 2.73 (s, 4H). 13C NMR (75 MHz, DMSO-d6) δ 177.6, 
166.0, 159.6 (d, J = 243.7 Hz), 160.0 (d, J = 11.7 Hz), 150.3, 146.4, 143.6, 138.6, 132.2 (d, J 
= 5.0 Hz), 128.4, 127.9, 126.5, 126.0, 119.5, 114.7 (d, J = 15.7 Hz), 112.3, 103.0 (d, J = 24.1 
Hz), 41.2, 28.2.
7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-(2-
fluoroethoxy)phenyl)quinoline-2-carboxamide (FEQCA; 18)—To a solution of the 
2-fluoro-4-hydroxyphenylboronic acid (50 mg, 0.320 mmol) and Na2CO3 (56.6 mg, 0.534 
mmol) in 1,4-dioxane : water (v/v, 10/1, 1.8 mL) was added compound 11 (80.0 mg, 0.267 
mmol) and Pd(PPh3)4 (30.9 mg, 0.0267 mmol) under Ar. The mixture was stirred at 100°C 
for 4 h, then quenched with water (3 mL) and extracted with ethyl acetate (5 mL × 3). The 
combined organic layers were washed with saturated aqueous sodium chloride, dried over 
MgSO4 and concentrated in vacuo. The residue was used without further purification. To the 
residue solution in DMF (1.5 mL) was added 1-fluoro-2-iodoethane (112 mg, 0.640 mmol) 
and Cs2CO3 (209 mg, 0.640 mmol). The mixture was stirred at room temperature overnight, 
then quenched with saturated aqueous KH2PO4 (5 mL). The combined organic layers were 
washed with saturated aqueous sodium chloride, dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash chromatography on silica gel (hexanes to ethyl 
acetate gradient column) to yield the compound 14 as white solid (45% for two steps, 50.6 
mg) and used directly in the next step. To the solution of compound 14 (42.1 mg, 0.1 mmol) 
in acetone : water (v/v, 2/1, 2 mL) was added sodium percarbonate (78 mg, 0.50 mmol). The 
mixture was stirred at room temperature for 4h, then added ethyl acetate (5 mL) and 
extracted with ethyl acetate (5 mL × 3). The residue was purified by flash chromatography 
on silica gel (hexanes to ethyl acetate gradient column) to yield FEQCA (18) as white solid 
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(60%, 26.3 mg). Rf = 0.2 (Hexanes/EtOAc = 1:3). 1H NMR (300 MHz, DMSO-d6) δ 8.34 
(s, 1H), 8.03 (s, 1H), 7.99 (s, 1H), 7.83 (s, 1H), 7.69 – 7.59 (m, 2H), 7.47 (t, J = 8.6 Hz, 1H), 
7.45 – 7.02 (m, 2H), 4.79 (dt, J=47.9, 3.5 Hz), 4.78 (s, 2H), 4.37 (dt, J=30.0, 3.5 Hz), 2.73 
(s, 4H). 13C NMR (75 MHz, DMSO-d6) δ 178.1, 166.4, 160.0 (d, J = 243.8 Hz), 160.6 (d, J 
= 11.1 Hz), 150.7, 146.8, 143.6, 139.2, 134.7 (d, J = 4.7 Hz), 128.9, 128.4, 126.7, 126.3, 
120.0, 117.1 (d, J = 15.8 Hz), 112.0, 103.0 (d, J = 25.7 Hz), 82.4 (d, J = 165.6 Hz), 68.2 (d, J 
= 18.8 Hz), 41.6, 28.6.
7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-(3-
fluoropropoxy)phenyl)quinoline-2-carboxamide (FPQCA; 19)—To a solution of 
the 2-fluoro-4-hydroxyphenylboronic acid (50 mg, 0.320 mmol) and Na2CO3 (56.6 mg, 
0.534 mmol) in 1,4-dioxane : water (v/v, 10/1, 1.8 mL) was added compound 11 (80.0 mg, 
0.267 mmol) and Pd(PPh3)4 (30.9 mg, 0.0267 mmol) under Ar. The mixture was stirred at 
100°C for 4 h, then quenched with water (3 mL) and extracted with ethyl acetate (5 mL × 3). 
The combined organic layers were washed with saturated aqueous sodium chloride, dried 
over MgSO4 and concentrated in vacuo. The residue was used without further purification. 
To the residue solution in DMF (1.5 mL) was added 1-fluoro-3-iodopropane (120 mg, 0.640 
mmol) and Cs2CO3 (209 mg, 0.640 mmol). The mixture was stirred at room temperature 
overnight, then quenched with saturated aqueous KH2PO4 (5 mL). The combined organic 
layers were washed with saturated aqueous sodium chloride, dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(hexanes to ethyl acetate gradient column) to yield the compound 15 as white solid (47% for 
two steps, 54.6 mg) and used directly in the next step. To the solution of compound 15 (43.6 
mg, 0.1 mmol) in acetone : water (v/v, 2/1, 2 mL) was added sodium percarbonate (78 mg, 
0.50 mmol). The mixture was stirred at room temperature for 4 h, then added ethyl acetate (5 
mL) and extracted with ethyl acetate (5 mL × 3). The residue was purified by flash 
chromatography on silica gel (hexanes to ethyl acetate gradient column) to yield FPQCA 
(19) as white solid (53%, 24 mg). Rf = 0.2 (Hexanes/EtOAc = 1:3). 1H NMR (300 MHz, 
DMSO-d6) δ 8.33 (s, 1H), 8.02 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.69 – 7.57 (m, 2H), 7.46 
(t, J=8.6 Hz, 1H), 7.45 – 7.02 (m, 2H), 4.78 (s, 2H), 4.63 (dt, J = 47.3, 5.9 Hz), 4.19 (t, J = 
6.3 Hz), 2.73 (s, 4H), 2.22 – 2.07 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 178.1, 166.4, 
160.0(d, J = 244.4 Hz), 161.0 (d, J = 12.5 Hz), 150.7, 146.8, 143.7, 139.2, 132.6 (d, J = 5.0 
Hz), 128.9, 128.3, 126.8, 126.3, 120.0, 116.8 (d, J = 16.0 Hz), 112.0, 102.9 (d, J = 25.6 Hz), 
81.2 (d, J = 160.7 Hz), 64.7 (d, J = 5.3 Hz), 41.6, 64.7 (d, J = 19.6 Hz), 28.6.
Pharmacology
Cell line generation and thallium flux assays—In order to generate human mGlu2 
and mGlu3 stable cell lines to be used for thallium flux assays, human mGlu2 and mGlu3 
were prepared by PCR amplification of the entire coding sequence of each receptor and 
cloning into pIRES puro 3 (Invitrogen). For mGlu2 and mGlu3, the cloning sites were NheI/
NotI. HEK GIRK cells, generously provided by Lily Jan (University of California San 
Francisco, San Francisco, CA), were transfected with 24 μg of DNA using Fugene6 
(Promega), stable transfectants were selected with 1000 ng/mL puromycin dihydrochloride 
(Sigma-Aldrich, St. Louis, MO), and polyclonal human mGlu2 GIRK and mGlu3 GIRK cell 
lines were established. Cells were maintained following selection in 45% DMEM, 45% 
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Ham's F12, 10% FBS, 100 units/mL penicillin/streptomycin, 20 mM HEPES, pH 7.3, 1 mM 
sodium pyruvate, 2 mM glutamine, 700 μg/mL G418 (Mediatech, Inc., Herndon, VA), and 
600 μg/mL puromycin (growth media) at 37°C in the presence of 5% CO2. All cell culture 
reagents were purchased from Invitrogen Corp. (Carlsbad, CA) unless otherwise noted.
Human mGlu2 and mGlu3 thallium flux in vitro assays—Compound activity at 
mGlu2 and mGlu3 was assessed using thallium flux through GIRK channels, a method that 
has been described in detail.80,81 Briefly, cells were plated into 384-well, black-walled, 
clear-bottomed poly-D-lysine-coated plates at a density of 15,000 cells/20 µL/well in 
DMEM containing 10% dialyzed FBS, 20 mM HEPES, and 100 units/mL penicillin/
streptomycin (assay media). Plated cells were incubated overnight at 37°C in the presence of 
5% CO2. The following day, the medium was exchanged from the cells to assay buffer 
[Hanks’ balanced salt solution (Invitrogen) containing 20 mM HEPES, pH 7.3] using an 
ELX405 microplate washer (BioTek), leaving 20 µL/well, followed by the addition of 20 µL/
well FluoZin2-AM (330 nM final concentration) indicator dye (Invitrogen; prepared as a 
stock in DMSO and mixed in a 1:1 ratio with Pluronic acid F-127) in assay buffer. Cells 
were incubated for 1 h at room temperature, and the dye exchanged to assay buffer using an 
ELX405, leaving 20 µL/well. For concentration-response curve experiments, compounds 
were serially diluted 1:3 into 10 point concentration response curves and were transferred to 
daughter plates using an Echo acoustic plate reformatter (Labcyte, Sunnyvale, CA). Test 
compounds were diluted to 2 times their final desired concentration in assay buffer (0.3% 
DMSO final concentration). Agonists were diluted in thallium buffer [125 mM sodium 
bicarbonate (added fresh the morning of the experiment), 1 mM magnesium sulfate, 1.8 mM 
calcium sulfate, 5 mM glucose, 12 mM thallium sulfate, and 10 mM HEPES, pH 7.3] at 5 
times the final concentration to be assayed. Cell plates and compound plates were loaded 
onto a kinetic imaging plate reader (FDSS 6000 or 7000; Hamamatsu Corporation, 
Bridgewater, NJ). Appropriate baseline readings were taken (10 images at 1 Hz; excitation, 
470 ± 20 nm; emission, 540 ± 30 nm) and test compounds were added in a 20 µL volume 
and incubated for approximately 1 hour at room temperature before the addition of 10 µL of 
thallium buffer with or without an EC80 concentration of the agonist glutamate for potency 
evaluation experiments or with a full concentration-response of glutamate for Schild analysis 
experiments. After the addition of agonist, data were collected for approximately an 
additional 2.5 min. Data were analyzed using Excel (Microsoft Corp, Redmond, WA). The 
slope of the fluorescence increase beginning 5 s after thallium/agonist addition and ending 
15 s after thallium/agonist addition was calculated, corrected to vehicle and maximal agonist 
control slope values, and plotted in using either XLfit (ID Business Solutions Ltd) or Prism 
software (GraphPad Software, San Diego, CA) to generate concentration-response curves. 
Potencies were calculated from fits using a four-point parameter logistic equation.
Measurement of physicochemical properties
Measurement of partition coefficient (LogP) (“shake flask method”)—The 
measurement of LogP value was performed by mixing test compound (50µL, 20 µM in 
DMSO) with n-octanol (475 µL) and water (475 µL) in a test tube. The n-octanol and water 
were pre-saturated with each other before use. The tube was vortexed for 1 min before 
shaken at 37°C overnight. Water phase and n-octanol phase (200 µL each) were aliquoted. 
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The amount of the test compound in each phase was determined by LC-MS/MS (Agilent 
6430 Triple Quad LC/MS). The LogP was calculated by Log [ratio between the amount of 
test compound in n-octanol and water solution]. The procedure was repeated triplicate and 
the value was shown in Table 1.
Measurement of pH stability—The stability of compounds in buffer solutions was 
measured using a HPLC method adapted from our previous protocol.82 Briefly, testing 
compounds 16, 18–19 (0.25 µmol) were each dissolved in 1 mL DMSO to make a stock 
solution. An aliquot (50 µL stock solution) was mixed with phosphate buffer (950 µL, 20 
mM, pH 7.4), boric acid-KCl-NaOH buffer (950 µL, 20 mM, pH 9.4) or sodium acetate-
KCl-HCl buffer (950 µL, 20 mM, pH 5.0) and incubated for 1 h at 37 °C. The percentage of 
the unchanged compound was monitored by HPLC (Luna analytical column, 4.6 × 250 mm, 
5 µm, CH3CN/H2O + 0.1% TFA).
Measurement of plasma stability—The stability of candidate compounds in rat serum 
was measured using a literature method.83 Briefly, the test was performed by mixing a 
candidate compound (10 µL, 10 µM in DMSO stock solution) with 250 µL aliquot of rat 
serum (Abcam, Inc. No. ab7488) in a test tube. The tube was vortexed before incubated at 
37°C for 60 min. The reaction was quenched by the addition of 250 µL ice-cold CH3CN, 
followed by centrifuge at 10,000 × g for 10 min. The amount of the test compound was 
quantified by LC-MS/MS (Agilent 6430 Triple Quad LC/MS). The percentage remaining 
was calculated by (peak area at 60 min) / (peak area at 0 min)×100%. The procedure was 
repeated at least triplicate and diltiazem was used as a positive control.
Measurement of liver microsomal stability—The stability of candidate compounds in 
liver microsomes was measured using a literature method.84 Briefly, the test was performed 
by mixing a candidate compound (0.5 µL, 2 mM in DMSO stock solution) with PBS (432 
µL) and 13 µL aliquot of Sprague-Dawley rat liver microsomes (Sigma-Aldrich, No. 
M9066) in a test tube. The tube was vortexed before shaken at 37°C for 5 min, followed by 
the addition of NADPH (50 µL, 10 mM in PBS stock solution). The mixture was incubated 
at 37°C for 60 min, and quenched by the addition of 250µL ice-cold CH3CN and centrifuge 
at 10,000 × g for 10 min. The amount of the test compound was quantified by LC-MS/MS 
(Agilent 6430 Triple Quad LC/MS). The percentage remaining was calculated by (peak area 
at 60 min)/(peak area at 0 min) × 100%. The procedure was repeated at least triplicate and 
verapamil was used as a positive control.
Radiochemistry
Radiolabeling of [11C]QCA—[11C]Methyl iodide ([11C]CH3I) was synthesized from 
cyclotron-produced [11C]CO2, which was produced by 14N(p, α)11C nuclear reaction. 
Briefly, [11C]CO2 was bubbled into a solution of LiAlH4 (0.4 M in THF, 300 μL). After 
evaporation, the remaining reaction mixture was treated with hydroiodic acid (57% aqueous 
solution, 300 μL). The resulting [11C]CH3I was transferred under helium gas with heating 
into a pre-cooled (−15 to −20 °C) reaction vessel containing precursor 17 (0.5 mg), NaOH 
(2.5 μL, 0.5 M) and anhydrous DMF (300 μL). After the radioactivity reached a plateau 
during transfer, the reaction vessel was warmed to 80 °C and maintained for 5 min. 
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CH3CN/H2O + 0.1% Et3N (v/v, 4/6, 0.5 mL) was added to the reaction mixture, which was 
then injected to a semi-preparative HPLC system. HPLC purification was completed on a 
Capcell Pak UG80 C18 column (10 mm ID × 250 mm) using a mobile phase of 
CH3CN/H2O + 0.1% Et3N (v/v, 4/6) at a flowrate of 6.0 mL/min. The retention time for 
[11C]QCA was 9.5 min. The radioactive fraction corresponding to the desired product was 
collected in a sterile flask, evaporated to dryness in vacuo, and reformulated in a saline 
solution (3 mL) containing 100 µL of 25% ascorbic acid in sterile water and 100 µL of 20% 
Tween® 80 in ethanol. (Note: We added ascorbic acid to prevent potential radiolysis and 
Tween® 80 to improve aqueous solubility.) The synthesis time was ca. 30 min from end-of-
bombardment. Radiochemical and chemical purity were measured by analytical HPLC 
(Capcell Pak UG80 C18, 4.6 mm ID × 250 mm, UV at 254 nm; CH3CN / H2O + 0.1% Et3N 
(v/v, 4/6) at a flowrate of 1.2 mL/min). The identity of [11C]QCA was confirmed by the co-
injection with unlabeled QCA. Radiochemical yield was 46% decay-corrected based on 
[11C]CO2 with >99% radiochemical purity and greater than 2 Ci/μmol specific activity.
Ex vivo biodistribution in mice
A solution of [11C]QCA (50 μCi/150–200 µL) was injected into DdY mice via the tail vein. 
These mice (n = 5, each time point) were sacrificed at 1, 5, 15, 30 and 60 min post tracer 
injection. Major organs, including whole brain, heart, liver, lung, spleen, kidneys, small 
intestine (including contents), muscle, testes, and blood samples were quickly harvested and 
weighted. The radioactivity present in these tissues was measured using a gamma counter 
(PerkinElmer, USA), and all radioactivity measurements were automatically decay corrected 
based on half-life of 11C. The results are expressed as the percentage of injected dose per 
gram of wet tissue (% ID/g) or standardized uptake value (SUV).
In vitro autoradiography
Rat brain was cut into 20 µM sections and stored at −80°C until they were used for 
experiment. The rat brain sections were pre-incubated with Tris-HCl buffer (50 mM), MgCl2 
(1.2 mM) and CaCl2 (2 mM) solution for 20 min at ambient temperature, followed by 
incubation with [11C]QCA (0.48 nM). For blocking studies, unlabeled QCA (1 µM) was 
added to incubation solution in advance to determine the specificity of radioligand binding. 
After incubation, brain sections were rinsed with ice-cold buffer three times for 2 min, 
dipped in cold distilled water for 10 sec. The brain sections were dried with cold air, then 
placed on imaging plates (BAS-MS2025, GE Healthcare, NJ, USA) for optimized contact 
periods. Autoradiograms were obtained and ROIs were carefully drawn with the reference of 
naked-eye observation. Radioactivity was expressed as photostimulated luminescene values 
per unit area (PSL/mm2) and measured by a Bio-Imaging analyzer system (BAS5000, 
Fujifilm)
Small-animal PET imaging studies
PET scans were acquired by an Inveon PET scanner (Siemens Medical Solutions, Knoxville, 
TN, USA). Sprague-Dawley rats were kept under anesthesia with 1–2% (v/v) isoflurane 
during the scan. The radiotracer (ca. 1 mCi/150–200 µL) was injected via a preinstalled 
catheter via tail vein. A dynamic scan in 3D list mode was acquired for 60 min. For 
pretreatment studies, QCA (1 mg/kg) pre-dissolved in 300 µL saline containing 10% ethanol 
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and 5% Tween® 80 was injected at 30 min via the tail vein catheter before the injection of 
[11C]QCA.
As we previously reported,78,79 the PET dynamic images were reconstructed using ASIPro 
VW software (Analysis Tools and System Setup/Diagnostics Tool, Siemens Medical 
Solutions). Volumes of interest, including the whole brain, cerebral cortex, cerebellum, 
striatum, thalamus and pons were placed using ASIPro software. The radioactivity was 
decay-corrected and expressed as the standardized uptake value. SUV = (radioactivity per 
mL tissue/injected radioactivity) × body weight.
Radiometabolite analysis
Following the intravenous injection of [11C]QCA, Sprague-Dawley rats were sacrificed at 5, 
20 and 60 min (n = 3 each time point). Blood and whole brain samples were quickly 
removed and the blood samples were centrifuged at 15,000 × g for 2 min at 4 °C to separate 
the plasma. The supernatant (0.5 mL) was then collected in a test tube containing CH3CN 
(0.5 mL) and the resulting mixture was vortexed for 15s and centrifuged at 15,000 × g for 2 
min for deproteinization. The rat brain was homogenized in an ice-cooled CH3CN/H2O (1 
mL, 1/1, v/v) solution. The homogenate was centrifuged at 150,000 rpm for 2 min at 4 °C 
and the supernatant was collected. The recovery of radioactivity into the supernatant was > 
90% based on the total radioactivity in the brain homogenate.
An aliquot of the supernatant (100 µL) obtained from the plasma or brain homogenate was 
injected into the radio-HPLC system, and analyzed using a Capcell Pak UG80 C18 column 
(4.6 mm ID × 250 mm) in a mobile phase of CH3CN / H2O + 0.1% Et3N (v/v, 45/55) at a 
flowrate of 1.0 mL/min. The retention time of [11C]QCA is 7.8 min. The percentage of 
[11C]QCA to total radioactivity (corrected for decay) on the HPLC charts was calculated as 
(peak area for [11C]QCA/total peak area) × 100.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
PET positron emission tomography
mGlu2 metabotropic glutamate receptor 2
PAM positive allosteric modulator






ADME absorption, distribution, metabolism and excretion
MPO multiparameter optimization
SUV standardized uptake value
TAC time-activity curve
%ID/g percentage of injected dose per gram of wet tissue
KO knockout
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Bcrp breast cancer resistance protein.
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PET tracers targeting mGlu2. While the majority of compounds in this figure have no 
selectivity data available in the primary literature, compound 2 showed mGlu2 selectivity 
greater than 350 fold over the other mGlu receptors.49
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In vitro evaluation of the potencies of QCA, FEQCA, FPQCA, and the control mGlu2/3 
NAM MNI-137 in mGlu2 GIRK (A) or mGlu3 GIRK (B) functional assays.
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QCA noncompetitively right-shifts the glutamate concentration-response for mGlu2 and 
decreases the maximal glutamate response (A) but has no effect on the glutamate 
concentration-response for mGlu3 (B).
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Ex vivo biodistribution in mice at five different time points (1, 5, 15, 30 and 60 min) post 
[11C]QCA injection. Data are expressed as %ID/g.
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In vitro autoradiography of [11C]QCA binding in rat brain sections. (A) Brain sections were 
treated with [11C]QCA in the absence (baseline) or presence of QCA, MNI-137, LY-487379 
(1 µM each). Cer, cerebellum; Hip, hippocampus; Cx, cortex; Str, striatum. (B) The 
radioactivity distribution was quantified in regional rat brain. The data are expressed as 
radioactivity per mm2 (n = 4). (C) Blocking studies. The data are normalized to % of 
radioactivity vs control (n = 4).
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PET/MRI fused images of [11C]QCA in rat brain: (A) baseline and (B) self-blocking with 
QCA (1 mg/kg). (C) Time-activity curves in whole brain under baseline and QCA self-
blocking.
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Percentages of unchanged [11C]QCA in rat brain tissue and plasma (n = 3) at 5, 20 and 60 
min post injection.
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PET/MRI fused images in the whole brain of (A) wild-type and (B) Pgp/Bcrp knockout 
mouse. (C) Time-activity curves of whole brain in wildtype and Pgp/Bcrp knockout mouse 
after [11C]QCA injection.
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Synthesis of quinoline 2-carboxamide analogs. (i) mCPBA, DCM, 1h; (ii) TMSCN, 
dimethylcarbamic chloride, DCM, 12 h, 74% for two steps; (iii) mCPBA, DCM, 40°C, 4 h; 
(iv) POCl3, DMF, CHCl3, 70°C, 6 h, 64% yield for two steps; (v) NBS, Benzoyl peroxide, 
CCl4, 85°C, 4 h, 60% yield; (vi) succinimide, Cs2CO3, DMF, 30 min, 80% yield; (vii) 
arylboronic acid, Pd(PPh3)4, Na2CO3, 1,4-dioxane, H2O, 100°C; (viii) Cs2CO3, DMF, 12 h, 
IC2H4F for 14, 45% yield over 2 steps from 11; IC3H6F for 15, 53% yield over 2 steps from 
11; (ix) sodium percarbonate, 55% yield for QCA (16) over 2 steps from 11, 51% yield for 
precursor 17 over 2 steps from 11, 60% yield for FEQCA (18), and 53% yield for FPQCA 
(19).
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Radiosynthesis of [11C]QCA (A) potential labeling methods; (B) 11CH3I labeling method.
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